- Home
- EFR vs DMAC Comparison
EFR vs DMAC Comparison
Compare EFR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- DMAC
- Stock Information
- Founded
- EFR 2003
- DMAC 2000
- Country
- EFR United States
- DMAC United States
- Employees
- EFR N/A
- DMAC N/A
- Industry
- EFR Trusts Except Educational Religious and Charitable
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- EFR Finance
- DMAC Health Care
- Exchange
- EFR Nasdaq
- DMAC Nasdaq
- Market Cap
- EFR 342.8M
- DMAC 321.5M
- IPO Year
- EFR N/A
- DMAC N/A
- Fundamental
- Price
- EFR $11.17
- DMAC $5.95
- Analyst Decision
- EFR
- DMAC Strong Buy
- Analyst Count
- EFR 0
- DMAC 4
- Target Price
- EFR N/A
- DMAC $15.50
- AVG Volume (30 Days)
- EFR 88.6K
- DMAC 315.3K
- Earning Date
- EFR 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- EFR 9.43%
- DMAC N/A
- EPS Growth
- EFR N/A
- DMAC N/A
- EPS
- EFR 1.69
- DMAC N/A
- Revenue
- EFR N/A
- DMAC N/A
- Revenue This Year
- EFR N/A
- DMAC N/A
- Revenue Next Year
- EFR N/A
- DMAC N/A
- P/E Ratio
- EFR $7.74
- DMAC N/A
- Revenue Growth
- EFR N/A
- DMAC N/A
- 52 Week Low
- EFR $10.95
- DMAC $3.19
- 52 Week High
- EFR $13.29
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- EFR 35.50
- DMAC 42.03
- Support Level
- EFR $11.09
- DMAC $5.26
- Resistance Level
- EFR $11.27
- DMAC $6.47
- Average True Range (ATR)
- EFR 0.10
- DMAC 0.41
- MACD
- EFR -0.00
- DMAC -0.10
- Stochastic Oscillator
- EFR 15.38
- DMAC 36.50
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.